The authors concluded that pharmacotherapy and psychotherapy are both effective for treating depression in older adults and treatment decisions should be based on other factors. Due to poor reporting of review methodology, the method of evidence synthesis and the inclusion of non-randomised evidence, it is not possible to determine the reliability of these conclusions.
Methods of synthesis
How were the studies combined? The studies were combined using a Mantel-Haenszel random-effects meta-analysis and pooled OR with 95% confidence intervals (CIs) were calculated for dichotomous data. Weighted mean effect sizes (d) with 95% CIs were calculated for depression scores.
How were differences between studies investigated?
Statistical heterogeneity between the studies was assessed using the Q statistic for effect size and the chi-squared statistic for ORs. Studies of pharmacotherapy and psychotherapy were analysed separately. Differences between the effect sizes for pharmacotherapy and psychotherapy were assessed by examining the degree of overlap of CIs and using the binomial effect size display in which the proportion of patients in each treatment group with above-average improvement was calculated. Pharmacotherapy studies were grouped according to drug class, while psychotherapy studies were subdivided into CBT and other psychotherapies and individual and group treatments, and these subgroups were also analysed separately. Meta-regression was used to examine the influence of various variables on the results: treatment, type of medical condition, in-patient, comorbidity of all patients, treatment duration, mean age, percentage of females, random assignment, blinding of the outcome assessors and intention-to-treat analysis.
Results of the review
Eighty-nine studies (5,328 patients) were included in the review.
Seventy-nine studies were randomised controlled trials. Seventy-three studies used blinded or masked outcome assessors. Forty-eight studies used intention-to-treat analysis. 3.47; 14 subgroups) for all psychotherapy studies. No statistically significant heterogeneity was detected.
Clinician-rated depression.
The pooled effect size for all studies was -0.80 (95% CI: -0.90, -0.69; 112 subgroups). The pooled effect size was -0.69 (95% CI: -0.81, 0.57; 77 subgroups) for all pharmacotherapy studies and -1.09 (95% CI: -1.26, -0.91; 35 subgroups) for all psychotherapy studies. For studies using different classes of pharmacotherapy, the pooled effect sizes were as follows: SSRIs, 0.48 (95% CI: -0.66, -0.30; 21 subgroups); TCAs, -0.93 (95% CI: -1.21, -0.65; 22 subgroups); MAO-Is, -0.79 (95% CI: -1.07, 0.51; 6 subgroups); other, -0.72 (95% CI: -0.95, -0.48; 28 subgroups). For studies of CBT the pooled effect size was -1.22 (95% CI: -1.42, -1.03; 26 subgroups), and for other forms of psychotherapy it was -0.75 (95% CI: -1.01, -0.49; 9 subgroups). Statistically significant heterogeneity between studies was found for all analyses with the exception of CBT and other psychotherapies.
Self-rated depression.
The pooled effect size for all studies was -0.76 (95% CI: -0.87, -0.64; 80 subgroups). The pooled effect size was -0.62 (95% CI: -0.79, 0.45; 28 subgroups) for all pharmacotherapy studies and -0.83 (95% CI: -0.98, -0.69; 52 subgroups) for all psychotherapy studies. For studies using different classes of pharmacotherapy, the effect sizes were as follows: SSRIs, 0.22 (95% CI: -0.35, -0.10; 4 subgroups); TCAs, -0.83 (95% CI: -1.20, -0.46; 10 subgroups); MAO-Is, -0.80 (95% CI: -1.19, 0.40; 3 subgroups); other, -0.67 (95% CI: -0.97, -0.37; 11 subgroups). For studies of CBT the effect size was -0.88 (95% CI: -1.05, -0.71; 40 subgroups), and for other forms of psychotherapy it was -0.69 (95% CI: -0.95, -0.42; 12 subgroups). Statistically significant heterogeneity between studies was found for all analyses with the exception of SSRIs, MAO-Is and other psychotherapies.
Pooled effect sizes for studies of major depression and for those including patients with minor depression or dysthymia were also calculated.
Clinician-rated depression. Treatment significantly improved effect sizes for clinician-rated depression compared with control for all studies (d -0.80, 95% CI: -0.90, -0.69, p<0.001; 112 subgroups), for pharmacotherapy studies (d -0.69, 95% CI: -0.81, -0.57, p<0.001; 77 subgroups) and for psychotherapy studies (d -1.09, 95% CI: -1.26, -0.91, p<0.001; 35 subgroups). Psychotherapy treatment showed larger effect sizes than pharmacological interventions (non-overlapping 95% CIs and above average improvement reported in 72.4% receiving psychotherapy versus 66.3% receiving pharmacotherapy). Control groups receiving medication reported greater improvements than psychotherapy groups (d = -0.91 versus d = -0.33).
Self-rated depression. Treatment significantly improved effect sizes for self-rated depression compared with control for all studies (d -0.76, 95% CI: -0.87, -0.64, p<0.001; 80 subgroups), for pharmacotherapy studies (d -0.62, 95% CI: -0.79, -0.45, p<0.001; 28 subgroups) and for psychotherapy studies (d -0.83, 95% CI: -0.98, -0.69, p<0.001; 52 subgroups). Psychotherapy and pharmacotherapy showed similar treatment effect (above average improvement reported in 69.2% receiving psychotherapy versus 64.8% receiving pharmacotherapy). Statistically significant heterogeneity was detected for all these analyses.
Studies comparing psychotherapy, pharmacotherapy and control (5 studies).
No differences were found between pharmacotherapy and psychotherapy in clinician-rated depression (d = -0.54 versus control and d = -0.41 versus control, respectively) or self-rated depression (d = -0.27 versus control and d = -0.19 versus control, respectively) effect sizes.
Subgroup analyses.
There were no significant differences between drug groups in clinician-rated depression. CBT was associated with larger effect size for clinician-rated depression than other types of psychotherapy, SSRIs, other drugs and all drugs combined. For those studies that included patients with minor depression and/or dysthymias, psychotherapy was associated with larger treatment effects for clinician-rated depression than pharmacotherapy. Results were reported for all these subgroups.
CRD commentary
The review question and the inclusion criteria were clear although broad. The authors searched a number of relevant databases and did not employ any language restrictions, thereby reducing the chance that relevant studies might have been omitted from the review. However, they did not report any attempts to identify unpublished studies, which might have increased the possibility of publication bias. The authors reported making some attempt to minimise bias and error in the extraction of data, but did not report the use of such procedures in the assessment of study validity or the selection of studies. The results of the validity assessment were used to inform the analysis only through the use of metaregression; subgroups or separate analyses within the primary analysis may have been more informative. The use of meta-analysis to combine randomised and non-randomised studies might not have been appropriate, and the high levels of statistically significant heterogeneity found in the analyses indicate that results were inconsistent among the studies.
Various potential sources of differences between the studies were examined. The reasons for the review's focus on effect sizes, rather than perhaps the more interpretable response and remission rates, were not clear. For studies that compared pharmacotherapy and psychotherapy, data were reported for each treatment versus control rather than a direct comparison between treatments; reasons for this were also unclear. Statements on relative efficacy were based predominantly on indirect comparisons. A very specific set of circumstances needs to be met for such a comparison to be valid, and some of these circumstances (e.g. comparability of placebo response rates) did not appear to have been met here. The authors' conclusions, that comparisons between pharmacotherapy and psychotherapy should be interpreted with caution, appear appropriate in view of the absence of adequate comparisons within studies. However, given the poor reporting of some review methodology and the high levels of clinical, methodological and statistical heterogeneity, it is not possible to determine the reliability of these conclusions.
Implications of the review for practice and research
Practice: The authors stated that treatment choice should be based on factors such as contraindications, treatment access, or patient preferences.
Research: The authors stated that further randomised controlled trials and a subsequent meta-analysis comparing pharmacotherapy, psychotherapy and a control condition in older depressed patients are required. Studies should also be conducted in patients with varying severity of depression, be set in usual clinical practice settings, compare interventions with other treatments (including electroconvulsive therapy), assess long-term outcomes, and evaluate the cost-effectiveness of interventions.
